ONCOCELL MDX
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, They have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of their pipeline.
ONCOCELL MDX
Social Links:
Founded:
2012-01-01
Address:
Corvallis, Oregon, United States
Country:
United States
Website Url:
http://www.oncocellmdx.com
Total Employee:
11+
Status:
Active
Total Funding:
22.2 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Domain Not Resolving WPForms Tailwind CSS
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Employees Featured
Founder
Investors List
Savitr Capital
Savitr Capital investment in Series B - OncoCell MDx
Official Site Inspections
http://www.oncocellmdx.com
- Host name: 151.101.194.159
- IP address: 151.101.194.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "OncoCell MDx"
OncoCell MDx - Crunchbase Company Profile & Funding
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In …See details»
OncoCell MDx - Craft
OncoCellMDx is a company dedicated to the development and commercialization of novel diagnostic tests using proprietary technologies. In particular, it utilizes noninvasive blood …See details»
Harry Stylli - Founder @ OncoCell MDx - Crunchbase
Harry Stylli is the chairman of OncoCellMDx Inc., a private company that develops and brings to market novel diagnostic tests based on proprietary technologies from Harvard Medical School. …See details»
OncoCell MDx - Overview, News & Similar companies - ZoomInfo
Jan 8, 2020 Popular Searches OncoCell MDx Oncocell Mdx Inc OncoCellMDx Inc SIC Code 80,807 NAICS Code 62,621 Show more. OncoCell MDx Org Chart. Phone Email. Angela …See details»
OncoCell MDx, Now Immunis.AI, to Present at Biotech Showcase
Jan 9, 2020 ROYAL OAK, Mich.--(BUSINESS WIRE)--OncoCell MDx, a privately held immunogenomics company with a patented liquid biopsy platform, today announced it has …See details»
OncoCell MDx - Funding, Financials, Valuation & Investors
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary. Search Crunchbase. ... How much funding has this …See details»
Executive and Investor in Biotherapeutics and Testing
May 15, 2018 In his role at OncoCellMDx, Dr. Harry Stylli strives to help physicians not only identify signatures of disease, but also gather crucial information about a cancer’s aggressiveness and staging.See details»
OncoCell MDx | Biotech Careers
OncoCellMDx is a privately held company developing diagnostic tests based on a noninvasive blood-based immuno-genomic assays that will aid the physician to better understand the …See details»
OncoCell MDx, Inc. Raises $22.2 Million in Series B Financing
Sep 11, 2019 ROYAL OAK, Mich.--(BUSINESS WIRE)--OncoCell MDx, Inc., a pan-disease immunogenomics platform company developing novel noninvasive blood-based tests to …See details»
Biotech, Pharmaceutical and Clinical Research Jobs | BioSpace
Biotech, Pharmaceutical and Clinical Research Jobs | BioSpaceSee details»
Biotech firm names chief medical officer - MITechNews
Jul 20, 2019 ROYAL OAK — OncoCell MDx has hired Kirk Wojno, M.D., as its chief medical officer. OncoCell MDx is developing new, noninvasive molecular diagnostic assays. Wojno, a …See details»
OncoCell MDx Appoints Marc Stapley to its Board of Directors
Jul 25, 2019 “I am excited to have Marc Stapley join the OncoCell Board of Directors. Marc brings a wealth of relevant experience as an executive and a board member to our team, …See details»
OncoCell MDx - Tech Stack, Apps, Patents & Trademarks
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary.See details»
OncoCell MDx Prepares for Commercialization with Appointment …
Jul 9, 2019 ROYAL OAK, Mich.--(BUSINESS WIRE)-- OncoCell MDx™, an immunogenomics platform company specializing in the delivery of novel, noninvasive molecular diagnostic …See details»
OncoCell MDx Announces Mark McDonough as New President
Apr 30, 2019 OncoCell MDx, a company developing novel noninvasive diagnostic and prognostic tests by harnessing the power of the immune system, today announced theSee details»
OncoCell MDx - Contacts, Employees, Board Members
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary. ... Products. Resources. Pricing. Resources. Log In. …See details»
OncoCell MDx Appoints Renowned Urologic Pathologist as Chief …
Jul 18, 2019 ROYAL OAK, Mich.--(BUSINESS WIRE)-- OncoCell MDx, an immunogenomics platform company specializing in the delivery of novel, noninvasive molecular diagnostic …See details»
OncoCell MDx Appoints Marc Stapley to its Board of Directors
Jul 25, 2019 Marc Stapley joins OncoCell MDx as a member of the Board of Directors. Stapley is currently the President and CEO of Helix and a member of the Glaukos Board of Directors.See details»
OncoCell Targets Cancer Prognostic Space With Phagocyte-Based ...
Apr 12, 2019 NEW YORK (GenomeWeb) – Liquid biopsy startup OncoCell aims to enter the cancer prognostic space with its noninvasive immuno-genomics RNA transcriptomics …See details»
OncoCell MDx Appoints Renowned Urologic Pathologist as Chief …
Jul 18, 2019 Kirk Wojno, M.D., is a nationally renowned urologic pathologist and currently serves as Chief Medical Officer for OncoCell MDx. (Photo: Business Wire)See details»